Loading
TLN-372 is an experimental small molecule pan-KRAS inhibitor from Treeline Biosciences, in phase 1 trials for KRAS-mutant solid tumours.
TLN-372 is a small molecule pan-KRAS inhibitor from Treeline Biosciences. Designed to achieve deep and sustained inhibition of KRAS across its mutant forms (pan-KRAS), not only G12C. Its furthest stage is phase 1, for KRAS-mutant solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry NCT07204340 phase 1 recruiting, alone and with cetuximab or pembrolizumab. Whether it works in people has not been established unless a trial below reports it.
Designed to achieve deep and sustained inhibition of KRAS across its mutant forms (pan-KRAS), not only G12C. Connects to KRAS.
1.TLN-372 slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TLN-372" OR ABSTRACT:"TLN-372") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TLN-372, not a curated reading list.
Shares KRAS, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares KRAS, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares KRAS, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares KRAS, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/